Cargando…

Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients

SIMPLE SUMMARY: The study objective was to determine if an SNP (single nucleotide polymorphism)-based immune multi-gene panel has the ability to predict adjuvant BCG (Bacillus Calmette–Guérin) immunotherapy responsiveness post-tumor resection in AJCC (American Joint Committee on Cancer) stages III a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramos, Romela Irene, Shaw, Misa A., Foshag, Leland, Stern, Stacey L., Rahimzadeh, Negin, Elashoff, David, Hoon, Dave S. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795941/ https://www.ncbi.nlm.nih.gov/pubmed/33396862 http://dx.doi.org/10.3390/cancers13010091

Ejemplares similares

γδ T cell activation may contribute to antitumor immunity stimulated by intralesional BCG immune therapy for cutaneous melanoma metastases
por: Ramos, Romela, et al.
Publicado: (2015)

A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients
por: Bustos, Matias A., et al.
Publicado: (2020)

Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette–Guérin
por: Yang, Junbao, et al.
Publicado: (2017)

Acetylated DNMT1 Downregulation and Related Regulatory Factors Influence Metastatic Melanoma Patients Survival
por: Zhang, Xiaoqing, et al.
Publicado: (2021)

Interleukin enhancer‐binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma
por: Zhang, Xiaoqing, et al.
Publicado: (2021)

A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients
por: Ono, Shigeshi, et al.
Publicado: (2015)

The melanoma brain metastatic microenvironment: aldolase C partakes in shaping the malignant phenotype of melanoma cells – a case of inter‐tumor heterogeneity
por: Izraely, Sivan, et al.
Publicado: (2020)

BCG immunotherapy of rat sarcomata.
por: Baldwin, R. W., et al.
Publicado: (1973)

BCG in Bladder Cancer Immunotherapy
por: Jiang, Song, et al.
Publicado: (2022)

Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis
por: Ramos, Romela Irene, et al.
Publicado: (2020)

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
por: Dupuis, Frantz, et al.
Publicado: (2018)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

BCG Immunotherapy of a Rat Sarcoma
por: Baldwin, R. W., et al.
Publicado: (1973)

Bladder Cancer Immunotherapy: BCG and Beyond
por: Askeland, Eric J., et al.
Publicado: (2012)

Reparameterized multiobjective control of BCG immunotherapy
por: Yue, Rongting, et al.
Publicado: (2023)

EpiMap: Fine-tuning integrative epigenomics maps to understand complex human regulatory genomic circuitry
por: Hoon, Dave S. B., et al.
Publicado: (2021)

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
por: Ralli, Massimo, et al.
Publicado: (2020)

Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
por: Amaral, Teresa, et al.
Publicado: (2020)

Current status and perspectives in immunotherapy for metastatic melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2018)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2020)

Combined Immunotherapy in Metastatic Melanoma with Unknown Primary
por: Khan, Yasir, et al.
Publicado: (2019)

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
por: Mignard, Claire, et al.
Publicado: (2018)

Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
por: Krimphove, Marieke J., et al.
Publicado: (2019)

A nano-enhanced vaccine for metastatic melanoma immunotherapy
por: Salotto, Katelyn E., et al.
Publicado: (2022)

Systemic Bacillus Calmette-Guérin (BCG) Infection With Renal Involvement: A Rare Complication of BCG Immunotherapy
por: Afonso, Raquel, et al.
Publicado: (2022)

An uncommon cause of miliary disease: intravesical BCG immunotherapy
por: Azevedo, Marcelo, et al.
Publicado: (2021)

The Vicious Cycle of Melanoma-Microglia Crosstalk: Inter-Melanoma Variations in the Brain-Metastasis-Promoting IL-6/JAK/STAT3 Signaling Pathway
por: Izraely, Sivan, et al.
Publicado: (2023)

Mycobacterium bovis Bacillus Calmette–Guérin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function
por: Lardone, Ricardo D., et al.
Publicado: (2017)

Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
por: Thatcher, N., et al.
Publicado: (1977)

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
por: Yu, Chune, et al.
Publicado: (2019)

Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma
por: Biteghe, Fleury Augustin Nsole, et al.
Publicado: (2020)

Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US
por: Moyers, Justin T., et al.
Publicado: (2020)

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2021)

Differences in and verification of genetic alterations in chemotherapy and immunotherapy for metastatic melanoma
por: Li, Yang, et al.
Publicado: (2021)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

A Rare Case of Metastatic Uveal Melanoma Responding to Immunotherapy
por: Fadel, Celine A, et al.
Publicado: (2022)

Abscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG
por: Vidovic, Dejan, et al.
Publicado: (2023)

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer
por: Bevers, R F M, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_k8l2c819lp0umbumt5vftf7q0m